Insider transactions

EDGAR

UROGEN PHARMA LTD.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-19.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
15 transactions, 125,343 shares
Sum of shares × price per share: 4,772,742.29

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 63

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-10-08 Filed 2026-10-09Degnan Chris Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Ordinary Shares
Acquired (A)4,483——6,763Direct (D) No
F1
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one ordinary share of the Issuer.
Open filing 0001437749-26-032421 Read from the filing’s XML Dispute this row
2026-10-08 Filed 2026-10-09Degnan Chris Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Ordinary Shares
Disposed (D)2,20236.69
80,791.38

Derived: shares × price per share. Exact value 80791.38.

4,561Direct (D) No
F2
  • F2 Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
Open filing 0001437749-26-032421 Read from the filing’s XML Dispute this row
2026-10-08 Filed 2026-10-09Degnan Chris Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Ordinary Shares (4,483)
Disposed (D)4,4830—4,484Direct (D) No
F1, F3
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one ordinary share of the Issuer.
  • F3 The reporting person was granted RSUs on October 8, 2024 representing 13,450 ordinary shares. The RSUs will vest in three equal annual installments from October 8, 2025.
Open filing 0001437749-26-032421 Read from the filing’s XML Dispute this row
2026-09-08 Filed 2026-09-09Smith Jason Drew Officer: General Counsel
S

Open market or private sale of non-derivative or derivative security

Ordinary Shares
Disposed (D)1,51942.54
64,618.26

Derived: shares × price per share. Exact value 64618.26.

53,141Direct (D) No
F2
  • F2 Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
Open filing 0001437749-26-029963 Read from the filing’s XML Dispute this row
2026-09-08 Filed 2026-09-09Schoenberg Mark Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Ordinary Shares
Disposed (D)87142.92
37,383.32

Derived: shares × price per share. Exact value 37383.32.

59,882Direct (D) No
F2
  • F2 Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
Open filing 0001437749-26-029965 Read from the filing’s XML Dispute this row
2026-09-07 Filed 2026-09-09Smith Jason Drew Officer: General Counsel
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Ordinary Shares
Acquired (A)3,334——54,660Direct (D) No
F1
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one ordinary share of the Issuer.
Open filing 0001437749-26-029963 Read from the filing’s XML Dispute this row
2026-09-07 Filed 2026-09-09Smith Jason Drew Officer: General Counsel
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Ordinary Shares (3,334)
Disposed (D)3,3340—0Direct (D) No
F1, F3
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one ordinary share of the Issuer.
  • F3 The reporting person was granted RSUs on September 7, 2023 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024.
Open filing 0001437749-26-029963 Read from the filing’s XML Dispute this row
2026-09-07 Filed 2026-09-09Schoenberg Mark Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Ordinary Shares
Acquired (A)1,667——60,753Direct (D) No
F1
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one ordinary share of the Issuer.
Open filing 0001437749-26-029965 Read from the filing’s XML Dispute this row
2026-09-07 Filed 2026-09-09Schoenberg Mark Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Ordinary Shares (1,667)
Disposed (D)1,6670—0Direct (D) No
F1, F3
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one ordinary share of the Issuer.
  • F3 The reporting person was granted RSUs on September 7, 2023 representing 5,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024.
Open filing 0001437749-26-029965 Read from the filing’s XML Dispute this row
2026-08-26 Filed 2026-08-28Robinson James A. Jr. Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

ordinary shares
Acquired (A)2,000——8,000Direct (D) No
F1
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one ordinary share of the Issuer
Open filing 0001437749-26-029175 Read from the filing’s XML Dispute this row
2026-08-26 Filed 2026-08-28Robinson James A. Jr. Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Unit — underlying Ordinary Shares (2,000)
Disposed (D)2,0000—0Direct (D) No
F1
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one ordinary share of the Issuer
Open filing 0001437749-26-029175 Read from the filing’s XML Dispute this row
2026-08-20 Filed 2026-08-24Schoenberg Mark Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

ordinary shares
Disposed (D)60,67747.05
2,854,852.85

Derived: shares × price per share. Exact value 2854852.85.

59,086Direct (D) No
F1
  • F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.30 to $49.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001437749-26-028840 Read from the filing’s XML Dispute this row
2026-07-09 Filed 2026-07-10Schoenberg Mark Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Ordinary Shares
Disposed (D)10,00040
400,000

Derived: shares × price per share. Exact value 400000.

119,763Direct (D) Yes
F1, F2
  • F1 Transaction made pursuant to a duly adopted trading plan under Rule 10b5-1(c). The adoption date of the referenced Rule 10b5-1(c) plan is August 15, 2025. This transaction represents the final sale under such trading plan.
  • F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 and $40.02. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
Open filing 0001437749-26-023290 Read from the filing’s XML Dispute this row
2026-06-22 Filed 2026-06-24Schoenberg Mark Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Ordinary Shares
Disposed (D)10,00035.01
350,100

Derived: shares × price per share. Exact value 350100.00.

129,763Direct (D) Yes
F1, F2
  • F1 Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). Adoption date of referenced 10b5-1(c) plan is: 08-15-2025.
  • F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 and $35.08. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
Open filing 0001437749-26-021523 Read from the filing’s XML Dispute this row
2026-06-22 Filed 2026-06-24Holden Stuart Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right ot buy) — underlying Ordinary Shares (20,000) — exercise price 34.99
Acquired (A)20,0000—20,000Direct (D) No
F1
  • F1 The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.
Open filing 0001437749-26-021515 Read from the filing’s XML Dispute this row
2026-06-22 Filed 2026-06-24WEN LEANA Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right ot buy) — underlying Ordinary Shares (10,000) — exercise price 34.99
Acquired (A)10,0000—10,000Direct (D) No
F1
  • F1 The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.
Open filing 0001437749-26-021511 Read from the filing’s XML Dispute this row
2026-06-22 Filed 2026-06-24WEN LEANA Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Unit — underlying Ordinary Shares (8,000)
Acquired (A)8,0000—8,000Direct (D) No
F2, F3
  • F2 Each restricted stock unit (RSU) represents a contingent right to receive one ordinary share of the Issuer.
  • F3 The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.
Open filing 0001437749-26-021511 Read from the filing’s XML Dispute this row
2026-06-22 Filed 2026-06-24Belldegrun Arie Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right ot buy) — underlying Ordinary Shares (20,000) — exercise price 34.99
Acquired (A)20,0000—20,000Direct (D) No
F1
  • F1 The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.
Open filing 0001437749-26-021509 Read from the filing’s XML Dispute this row
2026-06-22 Filed 2026-06-24Robinson James A. Jr. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right ot buy) — underlying Ordinary Shares (10,000) — exercise price 34.99
Acquired (A)10,0000—10,000Direct (D) No
F1
  • F1 The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.
Open filing 0001437749-26-021517 Read from the filing’s XML Dispute this row
2026-06-22 Filed 2026-06-24Robinson James A. Jr. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Unit — underlying Ordinary Shares (8,000)
Acquired (A)8,0000—8,000Direct (D) No
F2, F3
  • F2 Each restricted stock unit (RSU) represents a contingent right to receive one ordinary share of the Issuer.
  • F3 The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.
Open filing 0001437749-26-021517 Read from the filing’s XML Dispute this row
2026-06-22 Filed 2026-06-24BUTITTA CYNTHIA M Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right ot buy) — underlying Ordinary Shares (10,000) — exercise price 34.99
Acquired (A)10,0000—10,000Direct (D) No
F1
  • F1 The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.
Open filing 0001437749-26-021513 Read from the filing’s XML Dispute this row
2026-06-22 Filed 2026-06-24BUTITTA CYNTHIA M Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Unit — underlying Ordinary Shares (8,000)
Acquired (A)8,0000—8,000Direct (D) No
F2, F3
  • F2 Each restricted stock unit (RSU) represents a contingent right to receive one ordinary share of the Issuer
  • F3 The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.
Open filing 0001437749-26-021513 Read from the filing’s XML Dispute this row
2026-06-22 Filed 2026-06-24Wildman Daniel George Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right ot buy) — underlying Ordinary Shares (10,000) — exercise price 34.99
Acquired (A)10,0000—10,000Direct (D) No
F1
  • F1 The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.
Open filing 0001437749-26-021519 Read from the filing’s XML Dispute this row
2026-06-22 Filed 2026-06-24Wildman Daniel George Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Unit — underlying Ordinary Shares (8,000)
Acquired (A)8,0000—8,000Direct (D) No
F2, F3
  • F2 Each restricted stock unit (RSU) represents a contingent right to receive one ordinary share of the Issuer.
  • F3 The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.
Open filing 0001437749-26-021519 Read from the filing’s XML Dispute this row
2026-06-08 Filed 2026-06-09Schoenberg Mark Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Ordinary Shares
Acquired (A)10,000——144,985Direct (D) No
F1
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one ordinary share of the Issuer.
Open filing 0001437749-26-019964 Read from the filing’s XML Dispute this row
2026-06-08 Filed 2026-06-09Schoenberg Mark Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Ordinary Shares
Disposed (D)5,22227.30
142,560.6

Derived: shares × price per share. Exact value 142560.60.

139,763Direct (D) No
F2
  • F2 Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
Open filing 0001437749-26-019964 Read from the filing’s XML Dispute this row
2026-06-08 Filed 2026-06-09Schoenberg Mark Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Ordinary Shares (10,000)
Disposed (D)10,0000—0Direct (D) No
F1, F3
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one ordinary share of the Issuer.
  • F3 The reporting person was granted RSUs on June 8, 2023 representing 30,000 ordinary shares. The RSUs will vest in three equal annual installments from June 8, 2024.
Open filing 0001437749-26-019964 Read from the filing’s XML Dispute this row
2026-05-26 Filed 2026-05-27Robinson James A. Jr. Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

ordinary shares
Acquired (A)2,000——6,000Direct (D) No
F1
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one ordinary share of the Issuer
Open filing 0001437749-26-018442 Read from the filing’s XML Dispute this row
2026-05-26 Filed 2026-05-27Robinson James A. Jr. Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Unit — underlying Ordinary Shares (2,000)
Disposed (D)2,0000—2,000Direct (D) No
F1
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one ordinary share of the Issuer
Open filing 0001437749-26-018442 Read from the filing’s XML Dispute this row
2026-05-08 Filed 2026-05-11Schoenberg Mark Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Ordinary Shares
Disposed (D)10,00030
300,000

Derived: shares × price per share. Exact value 300000.

134,985Direct (D) Yes
F1, F2
  • F1 Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). Adoption date of referenced 10b5-1(c) plan is: 08-15-2025.
  • F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 and $30.05. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
Open filing 0001437749-26-016104 Read from the filing’s XML Dispute this row
2026-02-03 Filed 2026-02-11Smith Jason Drew Officer: General Counsel
S

Open market or private sale of non-derivative or derivative security

Ordinary Shares
Disposed (D)2,65419.69
52,257.26

Derived: shares × price per share. Exact value 52257.26.

52,934Direct (D) No
F2
  • F2 Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
Open filing 0001437749-26-003778 Read from the filing’s XML Dispute this row
2026-02-03 Filed 2026-02-11Smith Jason Drew Officer: General Counsel
S

Open market or private sale of non-derivative or derivative security

Ordinary Shares
Disposed (D)1,60819.69
31,661.52

Derived: shares × price per share. Exact value 31661.52.

51,326Direct (D) No
F2
  • F2 Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
Open filing 0001437749-26-003778 Read from the filing’s XML Dispute this row
2026-02-03 Filed 2026-02-11Smith Jason Drew Officer: General Counsel
S

Open market or private sale of non-derivative or derivative security

Ordinary Shares
Disposed (D)3,21719.69
63,342.73

Derived: shares × price per share. Exact value 63342.73.

55,588Direct (D) No
F2
  • F2 Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
Open filing 0001437749-26-003778 Read from the filing’s XML Dispute this row
2026-02-03 Filed 2026-02-04Schoenberg Mark Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Ordinary Shares
Disposed (D)1,84419.69
36,308.36

Derived: shares × price per share. Exact value 36308.36.

150,514Direct (D) No
F1
  • F1 Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
Open filing 0001437749-26-003040 Read from the filing’s XML Dispute this row
2026-02-03 Filed 2026-02-04Schoenberg Mark Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Ordinary Shares
Disposed (D)1,84319.69
36,288.67

Derived: shares × price per share. Exact value 36288.67.

148,671Direct (D) No
F1
  • F1 Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
Open filing 0001437749-26-003040 Read from the filing’s XML Dispute this row
2026-02-03 Filed 2026-02-04Schoenberg Mark Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Ordinary Shares
Disposed (D)3,68619.69
72,577.34

Derived: shares × price per share. Exact value 72577.34.

144,985Direct (D) No
F1
  • F1 Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
Open filing 0001437749-26-003040 Read from the filing’s XML Dispute this row
2026-01-31 Filed 2026-02-19Barrett Elizabeth A. Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Ordinary Shares (153,195)
Acquired (A)153,1950—153,195Direct (D) No
F1, F2
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one ordinary share of the Issuer.
  • F2 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2027, January 31, 2028 and January 31, 2029.
Open filing 0001437749-26-004638 Read from the filing’s XML Dispute this row
2026-01-31 Filed 2026-02-11Smith Jason Drew Officer: General Counsel
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Ordinary Shares
Acquired (A)5,500——55,472Direct (D) No
F1
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one ordinary share of the Issuer.
Open filing 0001437749-26-003778 Read from the filing’s XML Dispute this row
2026-01-31 Filed 2026-02-11Smith Jason Drew Officer: General Counsel
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Ordinary Shares
Acquired (A)3,333——58,805Direct (D) No
F1
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one ordinary share of the Issuer.
Open filing 0001437749-26-003778 Read from the filing’s XML Dispute this row
2026-01-31 Filed 2026-02-11Smith Jason Drew Officer: General Counsel
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Ordinary Shares
Acquired (A)6,667——49,972Direct (D) No
F1
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one ordinary share of the Issuer.
Open filing 0001437749-26-003778 Read from the filing’s XML Dispute this row
2026-01-31 Filed 2026-02-11Smith Jason Drew Officer: General Counsel
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Ordinary Shares (5,500)
Disposed (D)5,5000—5,500Direct (D) No
F1, F5
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one ordinary share of the Issuer.
  • F5 The reporting person was granted RSUs on January 31, 2024 representing 16,500 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2025.
Open filing 0001437749-26-003778 Read from the filing’s XML Dispute this row
2026-01-31 Filed 2026-02-11Smith Jason Drew Officer: General Counsel
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Ordinary Shares (3,333)
Disposed (D)3,3330—6,667Direct (D) No
F1, F3
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one ordinary share of the Issuer.
  • F3 The reporting person was granted RSUs on January 31, 2025 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2026.
Open filing 0001437749-26-003778 Read from the filing’s XML Dispute this row
2026-01-31 Filed 2026-02-11Smith Jason Drew Officer: General Counsel
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Ordinary Shares (6,667)
Disposed (D)6,6670—0Direct (D) No
F1, F4
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one ordinary share of the Issuer.
  • F4 The reporting person was granted RSUs on January 31, 2023 representing 20,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2024.
Open filing 0001437749-26-003778 Read from the filing’s XML Dispute this row
2026-01-31 Filed 2026-02-11Smith Jason Drew Officer: General Counsel
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Ordinary Shares (32,609)
Acquired (A)32,6090—32,609Direct (D) No
F1, F6
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one ordinary share of the Issuer.
  • F6 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2027, January 31, 2028 and January 31, 2029.
Open filing 0001437749-26-003778 Read from the filing’s XML Dispute this row
2026-01-31 Filed 2026-02-03Degnan Chris Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Ordinary Shares (32,609)
Acquired (A)32,6090—32,609Direct (D) No
F1, F2
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one ordinary share of the Issuer.
  • F2 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2027, January 31, 2028 and January 31, 2029.
Open filing 0001437749-26-002841 Read from the filing’s XML Dispute this row
2026-01-31 Filed 2026-02-03Schoenberg Mark Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Ordinary Shares
Acquired (A)3,333——145,692Direct (D) No
F1
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one ordinary share of the Issuer.
Open filing 0001437749-26-002843 Read from the filing’s XML Dispute this row
2026-01-31 Filed 2026-02-03Schoenberg Mark Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Ordinary Shares
Acquired (A)6,666——152,358Direct (D) No
F1
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one ordinary share of the Issuer.
Open filing 0001437749-26-002843 Read from the filing’s XML Dispute this row
2026-01-31 Filed 2026-02-03Schoenberg Mark Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Ordinary Shares
Acquired (A)3,334——142,359Direct (D) No
F1
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one ordinary share of the Issuer.
Open filing 0001437749-26-002843 Read from the filing’s XML Dispute this row
2026-01-31 Filed 2026-02-03Schoenberg Mark Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Ordinary Shares (3,333)
Disposed (D)3,3330—3,334Direct (D) No
F1, F4
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one ordinary share of the Issuer.
  • F4 The reporting person was granted RSUs on January 31, 2024 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2025.
Open filing 0001437749-26-002843 Read from the filing’s XML Dispute this row
2026-01-31 Filed 2026-02-03Schoenberg Mark Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Ordinary Shares (6,666)
Disposed (D)6,6660—13,334Direct (D) No
F1, F2
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one ordinary share of the Issuer.
  • F2 The reporting person was granted RSUs on January 31, 2025 representing 20,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2026.
Open filing 0001437749-26-002843 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,793 filings read, the latest filed 2026-11-17. Prior quarter ending 2026-06-30: 9,164 filings read.

Showing 1–50 of 224

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
RTW INVESTMENTS, LP 4,543,895 SH184,618,454 dollarsUnchanged Prior quarter: 4,543,895Open filing 0001493215-26-000214 Filed 2026-11-16 Dispute this row
BlackRock, Inc. Partly reported under another manager3,108,202 SH126,286,247 dollarsLower by 93,259 Prior quarter: 3,201,461Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
Kynam Capital Management, LP 2,434,207 SH98,901,830 dollarsUnchanged Prior quarter: 2,434,207Open filing 0001907884-26-000017 Filed 2026-11-16 Dispute this row
Jefferies Financial Group Inc. Partly reported under another manager2,199,652 SH89,371,861 dollarsUnchanged Prior quarter: 2,199,652Open filing 0000096223-26-000034 Filed 2026-11-05 Dispute this row
MORGAN STANLEY Partly reported under another manager2,174,808 SH88,362,486 dollarsLower by 401,555 Prior quarter: 2,576,363Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
ACORN CAPITAL ADVISORS, LLC 1,648,420 SH66,975,305 dollarsLower by 25,000 Prior quarter: 1,673,420Open filing 0001636587-26-000102 Filed 2026-11-16 Dispute this row
Opaleye Management Inc. 1,439,996 SH58,507,037 dollarsUnchanged Prior quarter: 1,439,996Open filing 0001420506-26-002880 Filed 2026-11-16 Dispute this row
AMERICAN CENTURY COMPANIES INC Partly reported under another manager1,375,304 SH55,878,693 dollarsLower by 310,415 Prior quarter: 1,685,719Open filing 0000748054-26-000008 Filed 2026-11-12 Dispute this row
D. E. Shaw Co., Inc. Partly reported under another manager1,283,889 SH52,164,410 dollarsHigher by 138,070 Prior quarter: 1,145,819Open filing 0001104659-26-128287 Filed 2026-11-16 Dispute this row
SILVERARC CAPITAL MANAGEMENT, LLC 1,148,689 SH46,671,234 dollarsLower by 153,290 Prior quarter: 1,301,979Open filing 0001420506-26-002577 Filed 2026-11-12 Dispute this row
ORBIMED ADVISORS LLC 988,487 SH40,162,227 dollarsHigher by 312,300 Prior quarter: 676,187Open filing 0001172661-26-005349 Filed 2026-11-16 Dispute this row
STATE STREET CORP Partly reported under another manager975,787 SH39,646,226 dollarsLower by 27,284 Prior quarter: 1,003,071Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
FRONTIER CAPITAL MANAGEMENT CO LLC 936,144 SH38,035,534 dollarsLower by 572,403 Prior quarter: 1,508,547Open filing 0001172661-26-005367 Filed 2026-11-16 Dispute this row
MPM BIOIMPACT LLC 909,691 SH36,960,745 dollarsLower by 23,724 Prior quarter: 933,415Open filing 0001193125-26-463462 Filed 2026-11-16 Dispute this row
GOLDMAN SACHS GROUP INC Partly reported under another manager848,342 SH34,468,135 dollarsHigher by 28,508 Prior quarter: 819,834Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row
Migdal Insurance Financial Holdings Ltd. Partly reported under another manager770,909 SH31,322,033 dollarsUnchanged Prior quarter: 770,909Open filing 0001178913-26-005061 Filed 2026-11-09 Dispute this row
Parkman Healthcare Partners LLC 750,202 SH30,480,707 dollarsHigher by 576,138 Prior quarter: 174,064Open filing 0001420506-26-002809 Filed 2026-11-16 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager617,513 SH25,086,227 dollarsHigher by 7,149 Prior quarter: 610,364Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
Woodline Partners LP 500,726 SH20,344,497 dollarsUnchanged Prior quarter: 500,726Open filing 0001172661-26-005063 Filed 2026-11-16 Dispute this row
Boxer Capital Management, LLC 500,000 SH20,315,000 dollarsUnchanged Prior quarter: 500,000Open filing 0001213900-26-120704 Filed 2026-11-16 Dispute this row
Elmind Capital, LP 491,100 SH19,953,393 dollarsHigher by 371,100 Prior quarter: 120,000Open filing 0001013594-26-001197 Filed 2026-11-16 Dispute this row
VANGUARD PORTFOLIO MANAGEMENT LLC 462,075 SH18,774,107 dollarsHigher by 5,517 Prior quarter: 456,558Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row
TWO SIGMA INVESTMENTS, LP 406,299 SH16,507,928 dollarsHigher by 257,336 Prior quarter: 148,963Open filing 0000899140-26-001341 Filed 2026-11-16 Dispute this row
ADAR1 Capital Management, LLC 369,785 SH15,024,365 dollarsHigher by 117,390 Prior quarter: 252,395Open filing 0001940272-26-000033 Filed 2026-11-16 Dispute this row
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. Partly reported under another manager366,973 SH14,910,113 dollarsNot in the prior quarter’s filings read Open filing 0000905148-26-004861 Filed 2026-11-16 Dispute this row
Walleye Capital LLC 348,116 SH14,143,953 dollarsNot in the prior quarter’s filings read Open filing 0001758720-26-000007 Filed 2026-11-13 Dispute this row
Hennion Walsh Asset Management, Inc. 309,584 SH12,578,398 dollarsHigher by 32,888 Prior quarter: 276,696Open filing 0002000324-26-005579 Filed 2026-10-13 Dispute this row
FEDERATED HERMES, INC. Partly reported under another manager305,217 SH12,400,967 dollarsHigher by 304,259 Prior quarter: 958Open filing 0001623632-26-001675 Filed 2026-11-12 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager303,188 SH12,318,529 dollarsLower by 1,382 Prior quarter: 304,570Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
NEXT CENTURY GROWTH INVESTORS LLC 297,083 SH12,070,482 dollarsNot in the prior quarter’s filings read Open filing 0001134007-26-000007 Filed 2026-11-13 Dispute this row
Schonfeld Strategic Advisors LLC 295,809 SH12,018,718 dollarsHigher by 263,350 Prior quarter: 32,459Open filing 0001665241-26-000003 Filed 2026-11-16 Dispute this row
OBERWEIS ASSET MANAGEMENT INC/ 295,625 SH12,011,244 dollarsNot in the prior quarter’s filings read Open filing 0001213900-26-120411 Filed 2026-11-16 Dispute this row
Qube Research Technologies Ltd 287,222 SH11,669,830 dollarsNot in the prior quarter’s filings read Open filing 0001729829-26-000018 Filed 2026-11-13 Dispute this row
AQR CAPITAL MANAGEMENT LLC Partly reported under another manager283,615 SH11,523,279 dollarsHigher by 134,387 Prior quarter: 149,228Open filing 0001167557-26-000324 Filed 2026-11-16 Dispute this row
MILLENNIUM MANAGEMENT LLC 268,902 SH10,925,488 dollarsHigher by 162,210 Prior quarter: 106,692Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row
UBS Group AG Partly reported under another manager266,218 SH10,816,436 dollarsHigher by 144,757 Prior quarter: 121,461Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
Nuveen, LLC Partly reported under another manager240,822 SH9,784,598 dollarsHigher by 148,720 Prior quarter: 92,102Open filing 0000930413-26-003284 Filed 2026-11-10 Dispute this row
BANK OF AMERICA CORP /DE/ Partly reported under another manager235,848 SH9,582,503 dollarsLower by 239,854 Prior quarter: 475,702Open filing 0000070858-26-000589 Filed 2026-11-16 Dispute this row
FMR LLC Partly reported under another manager230,871 SH9,380,292 dollarsHigher by 33,773 Prior quarter: 197,098Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
Soleus Capital Management, L.P. 230,274 SH9,356,033 dollarsLower by 599,536 Prior quarter: 829,810Open filing 0001802630-26-000008 Filed 2026-11-16 Dispute this row
RICE HALL JAMES ASSOCIATES, LLC 226,046 SH9,184,249 dollarsLower by 74,604 Prior quarter: 300,650Open filing 0001172661-26-005283 Filed 2026-11-16 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager210,356 SH8,508,900 dollarsHigher by 170,812 Prior quarter: 39,544Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
SUPERSTRING CAPITAL MANAGEMENT LP 184,392 SH7,491,847 dollarsLower by 6,921 Prior quarter: 191,313Open filing 0001931118-26-000011 Filed 2026-11-16 Dispute this row
Russell Investments Group, Ltd. Partly reported under another manager183,076 SH7,438,417 dollarsHigher by 88,097 Prior quarter: 94,979Open filing 0001193125-26-451241 Filed 2026-11-06 Dispute this row
ING GROEP NV 180,000 SH91,665,000 dollarsNot in the prior quarter’s filings read Open filing 0001140361-26-042914 Filed 2026-11-10 Dispute this row
WELLINGTON MANAGEMENT GROUP LLP Partly reported under another manager168,792 SH6,858,020 dollarsHigher by 53,430 Prior quarter: 115,362Open filing 0000902219-26-000323 Filed 2026-11-16 Dispute this row
J. Goldman Co LP 149,139 SH6,059,518 dollarsLower by 63,636 Prior quarter: 212,775Open filing 0001412741-26-000004 Filed 2026-11-16 Dispute this row
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 128,297 SH5,212,707 dollarsLower by 73 Prior quarter: 128,370Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row
Squarepoint Ops LLC Partly reported under another manager117,199 SH4,761,795 dollarsHigher by 105,500 Prior quarter: 11,699Open filing 0001642575-26-000012 Filed 2026-11-09 Dispute this row
Tidal Investments LLC Partly reported under another manager112,990 SH4,590,784 dollarsHigher by 11,153 Prior quarter: 101,837Open filing 0002000324-26-006122 Filed 2026-11-13 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • SG Americas Securities, LLC 2,052,906 SH
  • Point72 Asset Management, L.P. 1,525,549 SH
  • MENORA MIVTACHIM HOLDINGS LTD. 1,152,531 SH
  • HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND 387,074 SH
  • Sixth Street Partners Management Company, L.P. 128,370 SH
  • Ally Bridge Group (NY) LLC 69,183 SH
  • Annandale Capital, LLC 45,425 SH
  • Coastal Bridge Advisors, LLC 37,000 SH
  • J. Goldman Co LP 34,000 SH
  • ALGERT GLOBAL LLC 32,350 SH
  • Jupiter Topco LLC 19,100 SH
  • GROUP ONE TRADING LLC 18,000 SH
  • CAPITAL FUND MANAGEMENT S.A. 17,585 SH
  • GLENMEDE TRUST CO NA 17,206 SH
  • Birchview Capital, LP 16,487 SH
  • NEW YORK STATE COMMON RETIREMENT FUND 15,737 SH
  • Verdad Advisers, LP 14,440 SH
  • Integrated Wealth Concepts LLC 11,741 SH
  • INTECH INVESTMENT MANAGEMENT LLC 9,660 SH
  • JANE STREET GROUP, LLC 9,505 SH
  • Main Street Financial Solutions, LLC 8,190 SH
  • Baader Bank Aktiengesellschaft 8,000 SH
  • DIADEMA PARTNERS LP 7,137 SH
  • Quantbot Technologies LP 2,133 SH
  • Persistent Asset Partners Ltd 1,790 SH
  • Napier Financial, LLC 400 SH
  • Quarry LP 36 SH
  • NATIONAL BANK OF CANADA /FI/ 11 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
The Toronto-Dominion Bank Ordinary Shares, par value NIS 0.01 per share5.72,770,53009/30/2026 Filed 2026-11-13SCHEDULE 13G/AAmendment 2Open filing 0000947263-26-000091 Dispute this row
TD SECURITIES INC. Ordinary Shares, par value NIS 0.01 per share0.2115,70609/30/2026 Filed 2026-11-13SCHEDULE 13G/AAmendment 2Open filing 0000947263-26-000091 Dispute this row
BlackRock, Inc. Common Stock6.33,058,64809/30/2026 Filed 2026-10-27SCHEDULE 13G/AAmendment 1Open filing 0002012383-26-003732 Dispute this row
The Toronto-Dominion Bank Ordinary Shares, par value NIS 0.01 per share6.73,269,95706/30/2026 Filed 2026-08-12SCHEDULE 13G/AAmendment 1Open filing 0000947263-26-000072 Dispute this row
TD SECURITIES INC. Ordinary Shares, par value NIS 0.01 per share0.2101,30606/30/2026 Filed 2026-08-12SCHEDULE 13G/AAmendment 1Open filing 0000947263-26-000072 Dispute this row
The Toronto-Dominion Bank Ordinary Shares, par value NIS 0.01 per share5.42,616,71403/31/2026 Filed 2026-05-15SCHEDULE 13GOpen filing 0000947263-26-000047 Dispute this row
TD SECURITIES INC. Ordinary Shares, par value NIS 0.01 per share01,30603/31/2026 Filed 2026-05-15SCHEDULE 13GOpen filing 0000947263-26-000047 Dispute this row
Paradigm BioCapital Advisors LP Ordinary Shares, par value NIS 0.01 per share3.51,703,949.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0001104659-26-062615 Dispute this row
Paradigm BioCapital Advisors GP LLC Ordinary Shares, par value NIS 0.01 per share3.51,703,949.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0001104659-26-062615 Dispute this row
Senai Asefaw, M.D. Ordinary Shares, par value NIS 0.01 per share3.51,703,949.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0001104659-26-062615 Dispute this row
Paradigm BioCapital International Fund Ltd. Ordinary Shares, par value NIS 0.01 per share3.11,501,473.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0001104659-26-062615 Dispute this row
BlackRock, Inc. Common Stock5.22,519,77103/31/2026 Filed 2026-04-27SCHEDULE 13GOpen filing 0002012383-26-001661 Dispute this row
The Toronto-Dominion Bank Ordinary Shares, par value NIS 0.01 per share4.92,302,33412/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 1Open filing 0000947263-26-000006 Dispute this row
Paradigm BioCapital Advisors LP Ordinary Shares, par value NIS 0.01 per share9.04,216,084.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0001104659-25-112620 Dispute this row
Paradigm BioCapital Advisors GP LLC Ordinary Shares, par value NIS 0.01 per share9.04,216,084.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0001104659-25-112620 Dispute this row
Senai Asefaw, M.D. Ordinary Shares, par value NIS 0.01 per share9.04,216,084.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0001104659-25-112620 Dispute this row
Paradigm BioCapital International Fund Ltd. Ordinary Shares, par value NIS 0.01 per share8.03,722,066.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0001104659-25-112620 Dispute this row
The Toronto-Dominion Bank Ordinary Shares, par value NIS 0.01 per share6.93,190,51009/30/2025 Filed 2025-11-14SCHEDULE 13GOpen filing 0000947263-25-000010 Dispute this row
Cowen Financial Products LLC Ordinary Shares, par value NIS 0.01 per share0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 2Open filing 0001771015-25-000010 Dispute this row
Paradigm BioCapital Advisors LP Ordinary Shares, par value NIS 0.01 per share5.02,332,066.0008/05/2025 Filed 2025-08-12SCHEDULE 13GOpen filing 0001104659-25-076875 Dispute this row
Paradigm BioCapital Advisors GP LLC Ordinary Shares, par value NIS 0.01 per share5.02,332,066.0008/05/2025 Filed 2025-08-12SCHEDULE 13GOpen filing 0001104659-25-076875 Dispute this row
Senai Asefaw, M.D. Ordinary Shares, par value NIS 0.01 per share5.02,332,066.0008/05/2025 Filed 2025-08-12SCHEDULE 13GOpen filing 0001104659-25-076875 Dispute this row
Paradigm BioCapital International Fund Ltd. Ordinary Shares, par value NIS 0.01 per share4.42,056,187.0008/05/2025 Filed 2025-08-12SCHEDULE 13GOpen filing 0001104659-25-076875 Dispute this row
RA Capital Management, L.P. Ordinary Shares, par value NIS 0.01 per share0.00.0006/30/2025 Filed 2025-08-14SCHEDULE 13G/AAmendment 4Open filing 0001415889-25-022035 Dispute this row
Peter Kolchinsky Ordinary Shares, par value NIS 0.01 per share0.00.0006/30/2025 Filed 2025-08-14SCHEDULE 13G/AAmendment 4Open filing 0001415889-25-022035 Dispute this row
Rajeev Shah Ordinary Shares, par value NIS 0.01 per share0.00.0006/30/2025 Filed 2025-08-14SCHEDULE 13G/AAmendment 4Open filing 0001415889-25-022035 Dispute this row
RA Capital Healthcare Fund, L.P. Ordinary Shares, par value NIS 0.01 per share0.00.0006/30/2025 Filed 2025-08-14SCHEDULE 13G/AAmendment 4Open filing 0001415889-25-022035 Dispute this row
Morgan Stanley Ordinary Shares5.42,488,29906/30/2025 Filed 2025-08-06SCHEDULE 13GOpen filing 0000895421-25-000471 Dispute this row
Soleus Capital Master Fund, L.P. Ordinary Shares, par value NIS 0.01 per share4.72,185,000.0006/30/2025 Filed 2025-08-05SCHEDULE 13G/AAmendment 1Open filing 0001213900-25-072156 Dispute this row
Soleus Capital, LLC Ordinary Shares, par value NIS 0.01 per share4.72,185,000.0006/30/2025 Filed 2025-08-05SCHEDULE 13G/AAmendment 1Open filing 0001213900-25-072156 Dispute this row
Soleus Capital Group, LLC Ordinary Shares, par value NIS 0.01 per share4.72,185,000.0006/30/2025 Filed 2025-08-05SCHEDULE 13G/AAmendment 1Open filing 0001213900-25-072156 Dispute this row
Soleus Capital Management, L.P. Ordinary Shares, par value NIS 0.01 per share4.72,185,000.0006/30/2025 Filed 2025-08-05SCHEDULE 13G/AAmendment 1Open filing 0001213900-25-072156 Dispute this row
Soleus GP, LLC Ordinary Shares, par value NIS 0.01 per share4.72,185,000.0006/30/2025 Filed 2025-08-05SCHEDULE 13G/AAmendment 1Open filing 0001213900-25-072156 Dispute this row
Guy Levy Ordinary Shares, par value NIS 0.01 per share4.72,185,000.0006/30/2025 Filed 2025-08-05SCHEDULE 13G/AAmendment 1Open filing 0001213900-25-072156 Dispute this row
Cowen Financial Products LLC Ordinary Shares, par value NIS 0.01 per share6.93,190,51006/30/2025 Filed 2025-07-29SCHEDULE 13G/AAmendment 1Open filing 0001085146-25-004272 Dispute this row
BlackRock, Inc. Common Stock5.02,284,20606/30/2025 Filed 2025-07-16SCHEDULE 13G/AAmendment 1Open filing 0002052113-25-002462 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,481,460 filings read, dated 2004-06-14 to 2026-11-17: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
201517,836
2016222,374
2017211,722
2018222,268
2019215,153
2020166,955
2021249,834
2022187,707
2023229,670
2024234,041
2025235,520
2026260,174

Filings made before the SEC required XML are listed, not extracted.

Back to UROGEN PHARMA LTD.